NCT03990493View on ClinicalTrials.gov

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Melanoma
Interventions
BIOLOGICAL

Dengue Virus-1 #45AZ5 (PV-001-DV)

Intratumoral injection of PV-001-DV (1 injection)

BIOLOGICAL

Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)

IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)

Sponsors
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

PrimeVax Immuno-Oncology Inc.

INDUSTRY